|
1.
|
Davies L and Welch HG: Increasing
incidence of thyroid cancer in the United States, 1973–2002. JAMA.
295:2164–2167. 2006.
|
|
2.
|
National Cancer Information Center,
Goyang: National cancer statistics. http://www.cancer.go.kr/cms/statics/incidence/index.html#2uri
(Accessed June 2011).
|
|
3.
|
Goldgar DE, Easton DF, Cannon-Albright LA
and Skolnick MH: Systematic population-based assessment of cancer
risk in first-degree relatives of cancer probands. J Natl Cancer
Inst. 86:1600–1608. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Czene K, Lichtenstein P and Hemminki K:
Environmental and heritable causes of cancer among 9.6 million
individuals in the Swedish Family-Cancer Database. Int J Cancer.
99:260–266. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Canzian F, Amati P, Harach HR, et al: A
gene predisposing to familial thyroid tumors with cell oxyphilia
maps to chromosome 19p13.2. Am J Hum Genet. 63:1743–1748. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
McKay JD, Lesueur F, Jonard L, et al:
Localization of a susceptibility gene for familial nonmedullary
thyroid carcinoma to chromosome 2q21. Am J Hum Genet. 69:440–446.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7.
|
U.S. National Library of Medicine,
Bethesda: FOSB FBJ murine osteosarcoma viral oncogene homolog B.
http://www.ncbi.nlm.nih.gov/sites/entrez?Db=gene&Cmd=ShowDetailView&TermToSearch=2354uri
(Accessed September 2011).
|
|
8.
|
Siderovski DP, Blum S, Forsdyke RE and
Forsdyke DR: A set of human putative lymphocyte G0/G1 switch genes
includes genes homologous to rodent cytokine and zinc finger
protein-encoding genes. DNA Cell Biol. 9:579–587. 1990. View Article : Google Scholar
|
|
9.
|
Martin-Gallardo A, McCombie WR, Gocayne
JD, et al: Automated DNA sequencing and analysis of 106 kilobases
from human chromosome 19q13.3. Nat Genet. 1:34–39. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hess J, Angel P and Schorpp-Kistner M:
AP-1 subunits: quarrel and harmony among siblings. J Cell Sci.
117:5965–5973. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Ameyar M, Wisniewska M and Weitzman JB: A
role for AP-1 in apoptosis: the case for and against. Biochimie.
85:747–752. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Adjadj E, Schlumberger M and de Vathaire
F: Germ-line DNA polymorphisms and susceptibility to differentiated
thyroid cancer. Lancet Oncol. 10:181–190. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Siraj AK, Al-Rasheed M, Ibrahim M, et al:
RAD52 polymorphisms contribute to the development of papillary
thyroid cancer susceptibility in Middle Eastern population. J
Endocrinol Invest. 31:893–899. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Baida A, Farrington SM, Galofre P, Marcos
R and Velazquez A: Thyroid cancer susceptibility and THRA1 and
BAT-40 repeats polymorphisms. Cancer Epidemiol Biomarkers Prev.
14:638–642. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Eun YG, Hong IK, Kim SK, et al: A
polymorphism (rs1801018, Thr7Thr) of BCL2 is associated with
papillary thyroid cancer in Korean population. Clin Exp
Otorhinolaryngol. 4:149–154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Choi SJ, Kim TY, Lee JC, et al: Is routine
central neck dissection necessary for the treatment of papillary
thyroid microcarcinoma? Clin Exp Otorhinolaryngol. 1:41–45. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Zerial M, Toschi L, Ryseck RP, Schuermann
M, Muller R and Bravo R: The product of a novel growth factor
activated gene, fos B, interacts with JUN proteins enhancing their
DNA binding activity. EMBO J. 8:805–813. 1989.PubMed/NCBI
|
|
18.
|
Mumberg D, Lucibello FC, Schuermann M and
Muller R: Alternative splicing of fosB transcripts results in
differentially expressed mRNAs encoding functionally antagonistic
proteins. Genes Dev. 5:1212–1223. 1991. View Article : Google Scholar
|
|
19.
|
Metz R, Kouzarides T and Bravo R: A
C-terminal domain in FosB, absent in FosB/SF and Fra-1, which is
able to interact with the TATA binding protein, is required for
altered cell growth. EMBO J. 13:3832–3842. 1994.PubMed/NCBI
|
|
20.
|
Angel P and Karin M: The role of Jun, Fos
and the AP-1 complex in cell-proliferation and transformation.
Biochim Biophys Acta. 1072:129–157. 1991.PubMed/NCBI
|
|
21.
|
Karin M, Liu Z and Zandi E: AP-1 function
and regulation. Curr Opin Cell Biol. 9:240–246. 1997. View Article : Google Scholar
|
|
22.
|
Ransone LJ, Visvader J, Lamph WW,
Sassone-Corsi P and Verma IM: fos and jun interaction: the role of
the leucine zipper. Int J Cancer Suppl. 4:10–21. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Shaulian E and Karin M: AP-1 in cell
proliferation and survival. Oncogene. 20:2390–2400. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Van Dam H and Castellazzi M: Distinct
roles of Jun: Fos and Jun: ATF dimers in oncogenesis. Oncogene.
20:2453–2464. 2001.PubMed/NCBI
|
|
25.
|
Lee W, Mitchell P and Tjian R: Purified
transcription factor AP-1 interacts with TPA-inducible enhancer
elements. Cell. 49:741–752. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Vallone D, Battista S, Pierantoni GM, et
al: Neoplastic transformation of rat thyroid cells requires the
junB and fra-1 gene induction which is dependent on the HMGI-C gene
product. EMBO J. 16:5310–5321. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Liu G, Takano T, Matsuzuka F, Higashiyama
T, Kuma K and Amino N: Screening of specific changes in mRNAs in
thyroid tumors by sequence specific differential display: decreased
expression of c-fos mRNA in papillary carcinoma. Endocr J.
46:459–466. 1999. View Article : Google Scholar
|
|
28.
|
Chiappetta G, Tallini G, De Biasio MC, et
al: FRA-1 expression in hyperplastic and neoplastic thyroid
diseases. Clin Cancer Res. 6:4300–4306. 2000.PubMed/NCBI
|
|
29.
|
Kim YH, Oh JH, Kim NH, et al: Fra-1
expression in malignant and benign thyroid tumor. Korean J Intern
Med. 16:93–97. 2001.PubMed/NCBI
|
